Resveratrol, a naturally occurring phytoalexin, has long been known to have an important regulatory role of key functions in cell physiology. This multifunctional role of resveratrol is explained by its ability to interact with several targets of various cell pathways. In the recent past, synthetic chemical modifications have attempted to enhance the biological effects of resveratrol, including their anti-cancer properties. In this study, we investigated the molecular mechanisms of action of novel trans-restricted analogues of resveratrol in which the C-C double bond of the natural derivative has been replaced by diaryl substituted imidazole analogues.
Introduction
The health benefits of dietary phytochemicals have been largely demonstrated. Evidence from epidemiological studies, animal and human trials has suggested a strong association between the consumption of plant nutrients and the prevention of several human diseases including cancer, neurological disorders, obesity and atherosclerotic cardiovascular diseases. [1] [2] [3] The beneficial effects of dietary compounds have been attributed to the presence of several classes of molecules classified as carotenoids, phenolics, alkaloids, nitrogen-containing compounds, and organosulfur compounds. 4 Among these, phenolics are molecules possessing at least one aromatic ring with one or more hydroxyl groups into the phenyl ring with the potential to interact with cellular proteins. For this property, this class of metabolites is the subject of an extensive medical research for its ability to act as antioxidants and as anticancer agents via regulation of signal transduction pathways. Resveratrol (3,5,4'-trans-trihydroxystilbene) is a naturally occurring phenolic compound that is found in a variety of food sources, including wine, soy, peanuts, and peanut products. 5, 6 Since 1997 when Jang and colleagues reported the ability of resveratrol to inhibit carcinogenesis at multiple stages, 7 this molecule has gained particularly attention due to its inhibition of cellular events associated with tumor initiation, promotion and progression. 8 The cellular mechanisms contributing to the beneficial effects of resveratrol include the inactivation of multiple cellular pathways that regulate cell survival or apoptosis. Mechanisms include the downregulation of protein kinases including nuclear factor (NF)-κB, Wnt/β-catenin, protein kinase B (Akt), and mitogen-activated protein kinases (MAPK). [9] [10] [11] Parametric analysis of gene set enrichment (PAGE) indicated that resveratrol caused a significant alteration in 127 pathways including those involved in the regulation of cellular metabolism and Stat3 signalling. 8 These observations clearly reported the potential application of resveratrol in a clinical setting.
However, results obtained in vitro were only partially reported in vivo. 12 A major challenge that limits the potential application of resveratrol in human studies is represented by its poor bioavailability and the discrepancy between the concentrations used in cellular studies and those applied in vivo. Therefore, studies are ongoing to enhance the bioavailability of resveratrol by combinations with agents that can increase the in vivo metabolism, nanoparticle-mediated delivery, and the development of resveratrol based analogues. 13, 14 In this paper, we designed new analogues of resveratrol in which their stereochemically defined "trans" carbon-carbon double bond(s) has been locked into (hetero)cyclic moieties. 15 This strategic choice is founded on the fact that in the conversion of resveratrol into biologically inactive metabolites in vivo, the chemical liability of these double bonds, which suffer from trans-to-cis stereoisomerization and reduction to saturated carbon-carbon bonds, is involved. 16, 17 In detail, we plan to replace the trans-configured carbon-carbon double bond(s) of resveratrol scaffolds with five-membered heterocycles. In order to keep the trans geometry of the leading phytochemicals, the aromatic substituents were attached to the heterocyclic core in a 1,3-fashion.
The anti-tumorigenic activity of all these compounds was evaluated in the ovarian cancer cell line SKOV-3 and primary cancer cells isolated from the ascites of patients with metastatic ovarian cancer, and compared to that of resveratol. The abilities of these new derivates to reduce cell adhesion, cell migration and their potential synergy with chemotherapeutic drugs were also tested.
The tested derivates were shown to possess greater anti-tumorigenic properties than resveratrol.
This lays the foundation for future exploration in preclinical models.
Experimental

Compounds and reagents
Collagen type IV, MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide), and resveratrol were purchased from Sigma-Aldrich (St Louis, MO). Resveratrol was dissolved in dimethyl sulfoxide (DMSO) and immediately used. Epidermal growth factor (EGF), and
Interleukin-6 (IL-6) were from Prospec. Paclitaxel (PTX) was purchased from Tocris (Bristol, UK).
The pan-caspase inhibitor Z-VAD-FMK was form Abcam (Cambridge, UK). The following reagents were obtained from GE Healthcare (Little Chalfont, UK): Hybond ECL membrane and ECL western blotting detection reagents. Fibronectin was from BD Biosciences (San Jose, CA).
Primary antibodies were listed in (Supplementary Table 1 ). Secondary antibodies (HRP-conjugated)
were all from Santa Cruz Biotechnology (Dallas, Texas). Cell culture media and reagents were purchased from EuroClone (Milano, Italy). All other reagents were from standard commercial sources and were of the highest grade available.
The synthesis of resveratrol analogues was performed as previously described. 18 Briefly, 1,4-diaryl-1H-imidazoles Res_04, Res_08, Res_10, Res_15, Res_16, and Res_18, were prepared by a palladium-catalyzed Suzuki cross coupling reaction involving commercially available arylboronic acids and 4-bromo-1H-imidazole, followed by a copper-catalyzed Buchwald N-arylation of the resulting 4-aryl-1H-imidazoles with the required aryl bromides. On the contrary, 2,5-diaryl-1-methyl-1H-imidazole Res_09, Res_11, Res_12, Res_13, Res_14, and Res_19 were regioselectively obtained by a palladium and copper promoted sequential C5/C2 double arylation of 1-methyl-1H-imidazole with the required aryl bromides. All the compounds were isolated by flash chromatography on silica gel, and gave satisfactory mps, 1 H-NMR, 13 C-NMR, elemental analyses, and EIMS data. GLC analyses showed that their chemical purity was higher than 97%. The chemical structure of analogues is shown in Supplementary Fig. 1 . Analogues were all dissolved in in DMSO.
Cell culture
SKOV-3 human ovarian cancer cell line was grown in high-glucose Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2-mM L-glutamine, 100 U mL -1 penicillin, 100 µg mL -1 streptomycin, in a humidified atmosphere of 5% CO 2 at 37 °C.
Normal Human Dermal Fibroblasts (NHDF) were kindly provided by dr. Tiziana Cocco and dr.
Antonio Gaballo and maintained under standard culture conditions (complete DMEM, 5% CO 2 at 37 °C). MDA-231 cells were maintained under standard culture conditions (complete DMEM, 5% CO 2 at 37 °C).
Ascites were collected from chemotherapy-naïve ovarian cancer patients (n=3) diagnosed with serous adenocarcinoma and presented as stage III (FIGO classification) at the time of clinical intervention, as previously described. 19 All patients provided written informed consent.
Cell viability assay
Cells were plated at 5 x 10 3 / well in a 96-well plate and allowed to adhere to the plate overnight under the growth conditions described above. For determining cell viability, the MTT assay was used. After treatment, the culture medium was aspirated and 100 µl of RPMI-phenol free medium containing 10 µl of MTT stock solution, 5 mg mL -1 in phosphate-buffered saline (PBS) solution, was added to each well. After one hour of incubation, the MTT solution was removed and 100 µl of DMSO were added to dissolve MTT-formazan crystals. Absorbance of the converted dye was measured at a wavelength of 570 nm using an iMark microplate reader (BIORAD). The relative cell viability was expressed as a percentage of the untreated control group. The concentration of drug required to inhibit cell proliferation by 50% (IC50) was calculated using the Microsoft Excel software. Data were exported and analyzed using an Excel sheet and IC50 values were calculated by linear interpolation. IC values are expressed as mean ± standard deviation from at least ten independent experiments.
Cell adhesion assay
Cells were treated with resveratrol or analogues, maintained in suspension for 1 hour, and seeded onto 96-well plates coated with fibronectin (10 µg mL -1 ) or collagen type IV (10 µg mL 
Scratch wound assay
Cells were cultured 24-well plate until confluence and then wounded using a 200 µL pipette tip in the middle of well. Three wounds were made for each sample, and migration distance was 
Western blot analysis
Whole proteins were extracted in RIPA buffer (Cell Signaling, Danvers, MA) and quantified by the Bradford protein assay (BIORAD, Hercules, CA). Samples were separated by 12% SDS-PAGE and transferred to Hybond ECL nitrocellulose membranes (GE Healthcare, Little Chalfont, UK). The membranes were blocked with Blotto A (Santa Cruz, Dallas, Texas) at room temperature for 1 h, and incubated with the appropriate primary antibodies (see Supplementary Table 1) for 2 h at room temperature, as previously performed. 20 After two washes with a solution of TBS containing 0.1%
(v/v) tween 20 for 10 min, the membranes were incubated with secondary antibody HRPconjugated for 2 h at room temperature (standard dilution 1:2000). Blots were then developed using the Amersham ECL western blotting detection system (GE Healthcare, Little Chalfont, UK).
Densitometric quantitation of at least three indipendent replicates was done using ImageJ software.
Nucleic acid extraction, cDNA synthesis and qRT-PCR analysis
Total RNA was isolated from SKOV-3 cells using the Illustra triplePrep kit (GE Healthcare, Little Chalfont, UK). First-strand cDNA was synthesized using 1 µg of total RNA, oligo(dT)18 and 
Statistical analysis
Data were expressed as mean ± SD. Statistical analyses was determined by unpaired Student's t-test to compare between two groups and One-way ANOVA to compare three groups, analyzed using GraphPad PRISM software version 4.0. In all comparisons, p<0.05 was considered as statistically significant.
Results
The anti-proliferative effect of twelve analogues of resveratrol was evaluated in the human ovarian cancer cell line SKOV-3 using the MTT proliferation assay. Cells were treated with transresveratrol, used as a reference compound, and its analogues at the concentrations of 100 µM, 50 µM, and 25 µM, for 24 and 72 h ( Fig. 1) . Results show that all the analogues tested inhibited cell proliferation in a dose-and time-dependent manner (Fig. 1a) . As shown in table 1, the IC50 (drug concentration required to reduce of 50% cell viability) values calculated for resveratrol and analogues demonstrated that resveratrol derivates exhibited a higher anti-proliferative activity compared to resveratrol treatment alone. In detail, at 100 µM and after 24 h of exposure, analogues 4, 12, 13, 15, 16, and 19 produced the most pronounced effect with 100 % suppression of cellular growth (Fig. 1a) . In contrast, cell viability of NHDF cells was not affected after resveratrol analogues treatment (Supplementary Figure 2) . These data showed that analogues specifically reduced the growth of tumor cells but not normal cells in vitro.
Biological effects of analogues on cancer cells were first assessed by investigating the expression of proteins related to the regulation of cell viability and proliferation, cytoskeletal rearrangement, and cell-cell adhesion. Changes in cell morphology (loss of front-back polarity and gain of organized compact cell island) were also evaluated microscopically. For this screening, we selected analogues 4, 12, 13, 15, 16, and 19 that exhibited the greater anti-proliferative effect after 24 h of treatment.
We previously demonstrated the reduced phosphorylation of Akt/Gsk, and Erk as a mechanism of cell growth inhibition mediated by resveratrol, 21 leading to the hypothesis that these proteins may also be a candidate targets for analogues in ovarian cancer models. Therefore, in the present study we treated SKOV-3 cells with resveratrol and analogues at 50 µM for 1 h, and compared the expression levels of selected proteins by western blotting. As shown in Fig. 1b , the phosphorylation levels of Akt, Gsk, Erk, and cofilin (Cof) were significantly reduced in SKOV-3 after treatment. We also demonstrated the reduced protein expression of N-cadherin, cyclin D1, β-catenin, and Bcl2 in SKOV-3 cells treated with analogues ( Fig. 1b and Supplementary Figure 3) . Collectively, these results imply that analogues-mediated anti-proliferative effects are mediated through the downregulation of survival and proliferation protein kinase signaling pathways such as Akt and Erk.
In addition to these effects on cell proliferation, analogues demonstrated anti-tumor activities towards other cellular processes, including cell adhesion on extracellular matrix components (ECM) and cell migration.
To demonstrate this, we tested the adhesion of SKOV-3 cells on cell culture plastic wells coated with two different ECM components, fibronectin and collagen IV, for 30 min and 4 h. As a control, an equal number of cells was added to uncoated wells or wells coated with BSA. Figure 2 showed the reduced adhesion to matrix proteins in SKOV-3 cells treated with resveratrol or analogues after 30 min and 4 h. As shown, there was a significant decrease of cell adhesion after treatment with analogues 4, 10, 12, 13, 14, 15, 16, and 19.
In vitro scratch wound healing assays showed that the migration of SKOV-3 cells was significantly inhibited in the presence of analogues (Fig. 3a, b) . The rate of wound closure was different depending on analogues exposure, but significantly reduced compared to EGF-and IL-6-exposed cells. Fig. 3d shows representative images of a scraping assay after resveratrol and analogues treatment. The upper panels show the cell position at 0 hours, while the other panels the gap closure after EGF and IL-6 treatment alone or in co-stimulation with resveratrol and selected analogues.
Among the analogues tested, Res_4 showed the most pronounced effects on cell motility. We program, which is the reverse process of the epithelial mesenchymal transition (EMT). 22 We then examined whether analogues treatment would mediate a phenotypic and functional transition to MET. To demonstrate this, we performed a RT-qPCR analysis of EMT markers including key EMT-activating transcription factors, Zeb1, Zeb2, and Slug, to assess transcriptomic changes induced after resveratrol and analogues treatment (Fig. 4 ). Among the analogues tested, we selected
Res_15 for its enhanced anti-proliferative properties observed in the screening analysis. As shown, all five genes tested were down-regulated significantly after Res_15 treatment at 25 µM for 24 h.
On the contrary, after Res treatment at 100 µM for 24 h, only Vimentin expression level was reduced whereas Zeb2 and Slug increased significantly their expression (Fig. 4a) . Hence, Res_15 treatment affected better than resveratrol the expression of EMT markers in SKOV-3 cells. After demonstrating the reduced expression levels of these genes after analogues treatment, we determined phenotypic modifications induced in SKOV-3 after treatment with resveratrol or analogues to observe a potential reversion to an epithelial status (Fig. 4b) . The morphological appearance of treated SKOV-3 cells is illustrated in Fig. 4b . Despite the changes in EMT markers, the protein levels of the epithelial marker E-cadherin remained undetectable by western blotting (Fig. 1b) , with no significant reversal of cell morphology (Fig. 4b) . Similar results were obtained by treating the mesenchymal breast cancer model MDA-231 with analogues for 72 h and observing cell modifications by phase-contrast morphology (data not shown), leading to the conclusion that analogues reduced the expression of EMT markers and signalling EMT-related pathways without a complete molecular and phenotypic reversion into tight epithelial clusters.
These enhanced anti-cancer properties prompted us to investigate the action of analogues respect to classical resveratrol targets. Previous studies described the ability of resveratrol to activate SIRT1
and transcriptional factors that regulate mitochondrial biogenesis. We then investigated whether
Res_15 is able to activate these markers by RT-qPCR. As shown, SIRT1 and PGC1α mRNA levels were both higher after resveratrol and Res_15 treatment, but significantly lower in Res_15 treated cells (Supplementary Figure 4) . This suggests that the chemical structure of resveratrol is functionally important for driving the activation of these markers.
The effects of analogues were also tested using ex-vivo models. Three primary cell lines were obtained form the ascitic fluid of from late-stage (III) ovarian serous adenocarcinoma cancer patients. These cells were cultured in vitro as monolayer or forced to growth in suspension using poly-HEMA coated-plates. We tested the anti-proliferative effect of analogues on these cell lines, these results are shown in Table 2 . Reduced cell proliferation was demonstrated in ascitic cells compared with resveratrol treated cells. The most significant effects were obtained with Res_15, which was further studied for its ability to reduce growth is suspension and to reduce the expression of EMT markers (Fig. 5) . Primary ovarian cancer cells were maintained in suspension using poly-HEMA, which prevents cell attachment to the substratum and treated with resveratrol and Res_15 (Fig. 5a ). As shown, in primary tumor cells and tumor cell lines, the percentage of trypan blue positive cells significantly increased after resveratrol and Res_15 exposure ( Fig. 5a and b) .
Exposure of primary tumor cells to pan-caspase inhibitor Z-VAD-FMK, prevented resveratrol and
Res_15 cell death suggesting that apoptosis is involved in the mechanism of cell death induced after resveratrol and its analogue exposure (Fig. 5a ). The molecular mechanism underlying Res_15 effects were investigated with a particular interest towards the regulation of EMT markers, cell cycle and apoptosis proteins. Res_15 reduced N-cadherin, Vimentin, Slug, Zeb1, Cyclin D1, Bcl2
protein expression, and increased the expression of E-cadherin (Fig. 5c ).
EGF and IL-6 reduced the anti-cancer effect of the chemotherapeutic agent Paclitaxel (PTX) on tumor cells (Table 3 ). To verify if Res_15 analogue can interfere with this mechanism, we treated primary cells with PTX alone or in combination with EGF, IL-6, resveratrol and Res_15. As shown in Table 3 , EGF and IL-6 in combination with PTX reduced the responsiveness to drug treatment, while resveratrol and Res_15 restore chemotherapy response. Both molecules act by targeting the EGF-induced pErk activation, as shown in Fig. 5d .
Discussion
We previously demonstrated the anticancer properties of trans-restricted analogues of resveratrol in vitro against 60 human tumor cell lines (National Cancer Institute-60 panel). 18 Analogues displayed significant anti-proliferative potential across the NCI 60 panel. It remains to be determined the relationships among these analogues and resveratrol targets. In the present study, we provided further insights about the molecular targets of tested compounds using in vitro and ex vivo ovarian cancer cell models that we previously characterised for the resveratrol-mediated tumor suppressing activities.
Our in vitro studies confirmed that resveratrol analogues reduced proliferation, cell-adhesion on Overall, these data indicate the ability of analogues to be efficacious against several cellular targets, including EMT transcriptional regulators, a biological property that already characterises resveratrol and explains its multi-functional role in cell physiology. Importantly, analogues demonstrated a significant therapeutic potential at concentrations lower than those of resveratrol making these molecules closer to a possible clinical application.
One of the physiological consequences of resveratrol treatment is the activation of energy sensing bioenergetics markers and pathways. We investigated the extent of analogues effects on these resveratrol targets. SIRT1 and PPARGC1A are typically activated after resveratrol treatment. The present data demonstrate that the activation at mRNA level of SIRT1 and PGC1α were lower in Res_15 treated cells compared to resveratrol treatment. This results can be explained by considering i) the lower concentration of Res_15 that we used to stimulate cells; ii) a close structure-activity relationship that is important to activate these pathways. This hypothesis is also supported by other studies that described the structure-activity relationships of various polyphenols including resveratrol. 23 Despite highly similar in their chemical structure, analogues demonstrate different biological properties. As shown in Fig. 1 and Supplementary Fig. 3 , all six tested analogues exerted their effects by targeting cyclin D1, pErk (thr202/tyr204), pGsk (ser9), and pAkt (ser473). Three analogues (Res_15, Res_16, and Res_19) emerged in this screening because they showed greater effectiveness against some of the investigated targets ( Supplementary Fig. 3 ), N-cadherin, β-catenin, and Bcl2. These results provide a link between the chemical structure of analogues and their biological properties. This is also confirmed in the adhesion and wound experiments where analogues Res_4 showed greater efficacy compared to the other compounds.
Of various resveratrol analogues tested, Res_15 showed the greater anti-proliferative effect, and was further assayed for its anti-cancer properties against patients-derived ex-vivo cultures isolated Taken together, the current study highlights the potential of imidazole based resveratrol analogues, and indicates that Res_15 can be considered as a potential scaffold for the development of novel analogues with greater therapeutic potential against ovarian cancer. are the mean ± S.D of at least three independent experiments. Asterisks indicate a significant difference compared to res-treated samples. c) E-cadherin, N-cadherin, Vimentin, Slug, Zeb1, Cyclin D1, and Bcl2 protein expression was analyzed by western blot in ascites-derived ovarian cancer cells after treatment of 24 h with resveratrol or Res_15 at their IC50; α-tubulin was used as loading control. Densitometric quantification of three independent experiments (mean ± SD) was performed with ImageJ. Asterisks indicate a significant difference compared to resveratrol-treated samples. Student's t-test * p<0.05; ** p<0.01; *** p<0.001. d) Erk 1/2, and pErk (thr202/tyr204) protein expression were analysed by western blotting in ascites-derived cancer cells (OvCa1) treated with PTX (6 nM), EGF (100 ng mL -1 ), Res (40 µM), and Res_15 (10 µM) after 4h of stimulation, as described. Asterisks indicate a significant difference compared to resveratrol-treated samples. Table 1 . IC50 values were calculated by performing dose-response experiments with resveratrol and analogues in SKOV-3 cells.
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Supplementary Figure 2.
Resveratrol analogues effects on NHDF cell proliferation. Cells were treated with resveratrol or analogues at 25 µM for 72 h. Data shown represent the mean ± SD of three independent experiments and values were taken from at least six wells from each experiment.
Supplementary Figure 3.
Densitometric analysis of western blotting data. Results (mean ± SD; n = 3) are expressed as fold change of CTR values, and represent the ratio between N-cadherin, Cyclin D1, β-catenin, Bcl2, and α-tubulin levels. pCof, pErk, pGsk, and pAkt were normalised over total Cof, Erk, Gsk, Akt. Data were analyzed by Student's t-test. * p<0.05; ** p<0.01; *** p<0.001 as compared with resveratrol treated cells.
Supplementary Figure 4 . qPCR analysis on the expression of resveratrol targets in SKOV-3 cells treated for 24 h with Res and Res_15 at the concentration of 100 uM and 25 uM, respectively. Data are represented as mean ± SD of three independent experiments. The only asterisks indicate a significant difference compared to control, whereas asterisks above a line represent a significant difference between resveratrol and Res_15 treated samples. One-way ANOVA analysis * p<0.05; ** p<0.01; *** p<0.001.
